2′,3′-Dideoxyguanosine | CAS:85326-06-3

We serve 2′,3′-Dideoxyguanosine CAS:85326-06-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
2',3'-Dideoxyguanosine

Chemical Name:2',3'-Dideoxyguanosine
CAS.NO:85326-06-3
Synonyms:2-amino-9-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one
Molecular Formula:C10H13N5O3
Molecular Weight:251.24200
 
Physical and Chemical Properties:
Density:1.91
Boiling point:632.1ºC
Flash point:336.1ºC
 
Specification:
Appearance:White to off-white powder
Assay(HPLC):≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:2',3'-Dideoxyguanosine is used as antiviral agent



Contact us for information like 2-amino-9-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2′,3′-Dideoxyguanosine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2′,3′-Dideoxyguanosine Use and application,2-amino-9-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one technical grade,usp/ep/jp grade.


Related News: Cases recorded in Thailand, Taiwan, Germany, Vietnam, Japan, France and the United States involved patients who had not been to China.Bromoacetyl chloride manufacturer Cases recorded in Thailand, Taiwan, Germany, Vietnam, Japan, France and the United States involved patients who had not been to China.Cyclopropyl-2-fluoro benzyl ketone supplier In these situations, the API is not a single substance but the culmination of various ingredients.(2E)-2-(1,2,6,7-tetrahydrocyclopenta[e][1]benzofuran-8-ylidene)acetonitrile vendor In addition, due to the complex process of changing the API supplier and the risk of uncertainty, the viscosity of pharmaceutical and specialty API companies is usually better.The outlook for a cure is clouded with theoretical uncertainties and high-profile failures. Pharmaceutical giants including Johnson & Johnson, Merck and Pfizer have ditched their projects on unsatisfactory data.